Hester Biosciences Limited (HESTERBIO.NS)
INR 2459.15
(1.23%)
INR 2459.15
(1.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.59 Billion INR | 41.84% |
| 2022 | 2.53 Billion INR | -14.02% |
| 2021 | 2.94 Billion INR | 68.35% |
| 2020 | 1.75 Billion INR | -1.63% |
| 2019 | 1.77 Billion INR | 50.46% |
| 2018 | 1.18 Billion INR | 19.44% |
| 2017 | 990.4 Million INR | 5.43% |
| 2016 | 939.35 Million INR | 18.21% |
| 2015 | 794.66 Million INR | 4.74% |
| 2014 | 758.73 Million INR | 15.08% |
| 2013 | 659.33 Million INR | 19.44% |
| 2012 | 552.04 Million INR | 60.64% |
| 2011 | 343.65 Million INR | -16.39% |
| 2010 | 411.01 Million INR | 2.43% |
| 2009 | 401.25 Million INR | 5.95% |
| 2008 | 378.72 Million INR | 7.68% |
| 2007 | 351.72 Million INR | -2.0% |
| 2006 | 358.91 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -3.02 Billion INR | -184.26% |
| 2024 Q2 | 3.55 Billion INR | 217.21% |
| 2023 FY | 3.59 Billion INR | 41.84% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 3.91 Billion INR | 0.0% |
| 2023 Q4 | 3.59 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 2.53 Billion INR | 0.0% |
| 2022 Q2 | 3.53 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 2.53 Billion INR | -14.02% |
| 2021 Q2 | 1.8 Billion INR | 0.0% |
| 2021 Q4 | 2.94 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.94 Billion INR | 68.35% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 1.75 Billion INR | -1.63% |
| 2020 Q4 | 1.75 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 2.19 Billion INR | 0.0% |
| 2019 Q2 | 1.6 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 1.77 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 1.77 Billion INR | 50.46% |
| 2018 FY | 1.18 Billion INR | 19.44% |
| 2018 Q4 | 1.18 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 990.4 Million INR | 5.43% |
| 2016 FY | 939.35 Million INR | 18.21% |
| 2015 FY | 794.66 Million INR | 4.74% |
| 2014 FY | 758.73 Million INR | 15.08% |
| 2013 FY | 659.33 Million INR | 19.44% |
| 2012 Q2 | 719.44 Million INR | 0.0% |
| 2012 FY | 552.04 Million INR | 60.64% |
| 2012 Q4 | 552.04 Million INR | 0.0% |
| 2011 FY | 343.65 Million INR | -16.39% |
| 2010 FY | 411.01 Million INR | 2.43% |
| 2009 FY | 401.25 Million INR | 5.95% |
| 2008 FY | 378.72 Million INR | 7.68% |
| 2007 FY | 351.72 Million INR | -2.0% |
| 2006 FY | 358.91 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | -42.013% |
| Ind-Swift Limited | 13.45 Billion INR | 73.279% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 26.151% |
| Sakar Healthcare Limited | 1.26 Billion INR | -184.554% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 97.638% |
| Innova Captab Limited | 4.89 Billion INR | 26.636% |
| Divi's Laboratories Limited | 18.99 Billion INR | 81.07% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 1.813% |
| Morepen Laboratories Limited | 4.45 Billion INR | 19.397% |
| Mankind Pharma Limited | 23.87 Billion INR | 84.943% |
| Sequent Scientific Limited | 8.27 Billion INR | 56.555% |
| Wanbury Limited | 3.15 Billion INR | -13.919% |
| Laurus Labs Limited | 42.71 Billion INR | 91.584% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 67.956% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 30.616% |
| Alembic Limited | 1.43 Billion INR | -151.01% |
| Hikal Limited | 12.99 Billion INR | 72.337% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 77.911% |
| Neuland Laboratories Limited | 5.49 Billion INR | 34.624% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 66.43% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 94.479% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 43.202% |
| Themis Medicare Limited | 1.88 Billion INR | -90.448% |
| RPG Life Sciences Limited | 1.38 Billion INR | -160.449% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 94.993% |
| Lupin Limited | 96.23 Billion INR | 96.265% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -358.613% |
| Wockhardt Limited | 39.87 Billion INR | 90.984% |
| Vaishali Pharma Limited | 371.16 Million INR | -868.502% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 56.431% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1111.322% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 94.133% |
| FDC Limited | 3.7 Billion INR | 3.087% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 96.639% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -458.288% |
| Eris Lifesciences Limited | 38.26 Billion INR | 90.606% |
| Venus Remedies Limited | 1.39 Billion INR | -158.093% |
| ZIM Laboratories Limited | 2.08 Billion INR | -72.76% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -70.459% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -2149.639% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -2.542% |
| Shilpa Medicare Limited | 12.93 Billion INR | 72.204% |
| Albert David Limited | 1.15 Billion INR | -212.556% |
| Ajanta Pharma Limited | 10.71 Billion INR | 66.437% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -76.712% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 74.491% |
| Gufic Biosciences Limited | 5.59 Billion INR | 35.806% |
| Windlas Biotech Limited | 1.76 Billion INR | -103.933% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -40.353% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -108.73% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -81.89% |
| Granules India Limited | 22.95 Billion INR | 84.34% |
| Aarti Drugs Limited | 11.5 Billion INR | 68.752% |
| Bal Pharma Limited | 2.51 Billion INR | -43.143% |
| Alkem Laboratories Limited | 48.6 Billion INR | 92.604% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.042% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -234.534% |
| Medicamen Biotech Limited | 940.36 Million INR | -282.268% |
| Unichem Laboratories Limited | 8.06 Billion INR | 55.452% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -451.102% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1144.713% |
| Valiant Laboratories Limited | 1.05 Billion INR | -239.682% |
| Orchid Pharma Limited | 3.84 Billion INR | 6.487% |
| Medico Remedies Limited | 438.24 Million INR | -720.255% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -57.012% |
| Ipca Laboratories Limited | 33.74 Billion INR | 89.347% |
| Brooks Laboratories Limited | 248.6 Million INR | -1345.98% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -208.504% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.359% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 95.619% |
| NATCO Pharma Limited | 10.53 Billion INR | 65.869% |
| Suven Life Sciences Limited | 148.62 Million INR | -2318.716% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -20.875% |
| Strides Pharma Science Limited | 37.68 Billion INR | 90.46% |
| Indoco Remedies Limited | 10.34 Billion INR | 65.243% |
| Alpa Laboratories Limited | 307.12 Million INR | -1070.453% |
| Lasa Supergenerics Limited | 541.92 Million INR | -563.324% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 7.66% |